Here are the Form 4 insider transactions from Hologic Inc (HOLX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow HOLX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HOLX filings page.
Hologic, Inc. executive Jan Verstreken reported changes to his equity awards in connection with the company’s closing merger with Hopper Parent Inc. At the merger’s effective time, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right worth up to $3.00 in cash, if payable. Outstanding stock options, restricted stock units and performance stock units held by Verstreken were cancelled or converted into cash- and CVR-based rights consistent with this merger consideration. As a result of the transaction, he no longer beneficially owns any shares of Hologic common stock.
Hologic Inc. reported that Brandon Schnittker, President, GYN Surgical, had his equity awards settled in connection with the company’s merger into a wholly owned subsidiary of Hopper Parent Inc. Each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right (CVR) for up to an additional $3.00 in cash.
Multiple non-qualified stock options, performance stock units and 17,644 shares of common stock were disposed of to the issuer, and performance stock units were certified and then converted into the cash-and-CVR merger consideration. As a result of the merger, Schnittker no longer beneficially owns any Hologic common stock, directly or indirectly.
Hologic Inc President, Diagnostic Solutions Jennifer M. Schneiders reported multiple equity award adjustments tied to the company’s merger. On April 7, 2026, she disposed of 41,462 shares of common stock back to the issuer and surrendered several non-qualified stock option grants covering 3,804, 4,058, 10,028 and 18,698 underlying shares.
Footnotes state that, under the October 21, 2025 merger agreement, each Hologic common share was converted into the right to receive $76.00 in cash plus a contingent value right of up to $3.00 in cash per share. Restricted stock units and performance stock units were converted into cash- and CVR-based rights and then cancelled. As a result of the merger, Schneiders no longer beneficially owns any Hologic common stock.
Hologic Inc.’s Chief Financial Officer Karleen Oberton reported the cash-out of her equity awards in connection with Hologic’s merger with Hopper Parent Inc. At the merger’s effective time, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right (CVR) representing up to an additional $3.00 in cash.
On the same date, Oberton disposed of multiple non‑qualified stock option grants covering tens of thousands of shares at exercise prices between $45.61 and $79.39, as well as performance stock units and 150,735 shares of common stock back to the issuer. A performance‑based award of 42,707 performance stock units was certified and then cancelled for the merger consideration. As a result of the merger, she no longer beneficially owns any Hologic common stock, with her equity position replaced by the cash and CVR rights defined in the merger agreement.
Hologic, Inc. Chief Operating Officer Mitchell D. Essex reported merger-related equity changes tied to the company’s acquisition. On April 7, 2026, his non‑qualified stock options covering 2,972, 11,596, 25,070 and 32,722 shares of common stock were disposed of back to the issuer, ending those option positions.
The filing also shows 46,154 performance stock units certified and then cancelled, and 77,694 shares of common stock disposed to the issuer at the merger’s effective time. Under the merger terms, each Hologic common share was converted into the right to receive $76.00 in cash plus a contingent value right for up to $3.00 in cash per share. As a result of these transactions, Essex no longer beneficially owns any Hologic common stock.
Hologic, Inc. completed a merger in which Hopper Merger Sub combined with the company, making Hologic a wholly owned subsidiary of Hopper Parent Inc. At the effective time, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right for up to an additional $3.00 in cash per share.
For General Counsel Anne M. Liddy, all outstanding stock options, performance stock units, restricted stock units, and 28,052 shares of common stock were disposed of to the issuer or converted into rights to receive the merger consideration. As a result of the merger, she no longer beneficially owns any Hologic common stock.
Hologic Inc. executive Mark W. Horvath has exited all company equity as part of a completed cash merger. On April 7, 2026, he disposed of 23,026 shares of Hologic common stock back to the company, along with multiple non-qualified stock options and performance stock units.
The option awards covering a total of 20,596 underlying shares at exercise prices ranging from $65.24 to $79.39 were canceled and converted into the merger consideration. In addition, 7,762 performance stock units were certified by the board’s compensation committee and then canceled for the same merger consideration.
Under the merger, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right that can pay up to $3.00 in cash. Following these transactions, Horvath no longer beneficially owns any Hologic common stock, and the dispositions reflect payouts under the merger agreement rather than open-market trading.
Hologic Inc. senior vice president of human resources Diana De Walt disposed of 7,603 shares of common stock in connection with the company’s merger into Hopper Parent Inc. Each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right (CVR) worth up to $3.00 in cash, if payable. As a result of this merger-related conversion, De Walt no longer beneficially owns any Hologic common shares.
Hologic, Inc. director Amy McBride disposed of her equity awards and shares in connection with the company’s merger. On April 7, 2026, multiple non-qualified stock option grants, each covering between 1,500 and 7,551 shares of common stock at exercise prices from $38.44 to $78.49, were reported as dispositions to the issuer, leaving 0 derivative securities outstanding for each grant.
On the same date, 25,784 shares of Hologic common stock were also reported as a disposition to the issuer. Under the merger, each share of common stock was converted into the right to receive $76.00 in cash plus one contingent value right for up to an additional $3.00 in cash per share. The filing notes that McBride’s time-vesting restricted stock units were converted into the same merger consideration and that she no longer beneficially owns any Hologic common stock.
Hologic, Inc. director Stacey D. Stewart reported returning stock awards to the company in connection with a completed merger. On April 7, 2026, he disposed of 15,049 non‑qualified stock options covering Hologic common stock at exercise prices between $64.36 and $78.49, plus 8,358 shares of common stock, all as issuer dispositions.
Footnotes explain that under an Agreement and Plan of Merger, each Hologic common share was converted into the right to receive $76.00 in cash and one contingent value right of up to $3.00 in cash. Time‑vesting restricted stock units were similarly converted, and Stewart no longer beneficially owns any Hologic common stock.
Hologic, Inc. director Christiana Stamoulis reported the cash-out of her equity in connection with a merger. All reported holdings, including 50,526 shares of common stock and several non-qualified stock option grants, were disposed of to the issuer, leaving her with no remaining Hologic equity.
Under the merger, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right that may pay up to an additional $3.00 in cash per share.
Hologic, Inc. director Nanaz Mohtashami reported dispositions tied to the company’s merger with Hopper Parent Inc. At the merger’s effective time, each Hologic common share converted into $76.00 in cash plus one contingent value right worth up to $3.00 in cash when and if payable.
On that date, Mohtashami disposed of non-qualified stock options covering 2,141, 4,536, and 5,535 shares at exercise prices of $71.45, $76.32, and $64.36, respectively, along with 7,371 common shares, all back to the issuer. The filing notes that, as a result of the merger, Mohtashami no longer beneficially owns any Hologic common stock.
Hologic Inc director Wayde D. McMillan reported the disposition of his company equity in connection with the closing of a merger. He surrendered 5,171 non-qualified stock options with a $61.27 exercise price and 4,932 shares of common stock back to the issuer.
Under the merger agreement with Hopper Parent Inc., each Hologic common share was converted into the right to receive $76.00 in cash plus one contingent value right that may pay up to an additional $3.00 in cash. McMillan’s time-vesting restricted stock units were similarly converted, and as a result he no longer beneficially owns any Hologic common stock.
Hologic Inc. director Martin D. Madaus reported dispositions of all remaining equity interests in connection with the company’s merger. On April 7, 2026, he surrendered 1,016 and 5,535 non-qualified stock options with exercise prices of $75.79 and $64.36 per share, respectively, plus 5,396 shares of common stock held directly and 5,445 shares held through a revocable trust, all as dispositions to the issuer.
Under the Merger Agreement, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right of up to $3.00 in cash per share. As a result of the merger, Madaus no longer beneficially owns any Hologic common stock, directly or indirectly.
Hologic CEO Stephen MacMillan reports the cancellation of his Hologic equity holdings in connection with the company’s merger. At the merger’s effective time, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right for up to an additional $3.00 in cash.
His time-vesting restricted stock units and performance stock units were converted into cash-based rights to the same merger consideration structure. Following these conversions and dispositions, the filing states that MacMillan no longer beneficially owns, directly or indirectly, any shares of Hologic common stock.
Hologic director Ludwig Hantson reported the disposition of his equity awards in connection with the company’s merger. On April 7, 2026, multiple non-qualified stock options covering thousands of shares of Hologic common stock and 16,146 common shares were disposed of to the issuer.
Under the merger agreement, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right, which may pay up to $3.00 in cash. Time-vesting restricted stock units held by Hantson were similarly converted into this merger consideration, and he no longer beneficially owns any Hologic common shares.
HOLOGIC INC director Charles J. Dockendorff disposed of all his company equity in connection with the company’s merger into Hopper Parent Inc. On the merger’s effective date, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right worth up to $3.00 in cash when and if payable. All reported non-qualified stock options and common shares, including those held through a revocable trust, were surrendered to the issuer, leaving Dockendorff with no direct or indirect beneficial ownership of Hologic common stock.
Hologic Inc.’s Principal Accounting Officer, Benjamin Jordan Cohn, reported the cash-out and cancellation of his equity awards in connection with the company’s merger. Multiple non-qualified stock options and 17,964 shares of common stock were disposed of back to the issuer.
Footnotes explain that, at the effective time of the merger, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right worth up to an additional $3.00 in cash per share. Time-vesting restricted stock units and performance stock units held by Cohn were similarly converted into rights to receive this merger consideration, and as a result he no longer beneficially owns any Hologic common stock.
Hologic Inc. General Counsel Anne M. Liddy reported a small share disposition related to taxes, not an open-market sale. On the transaction date, 185 shares of common stock were withheld at $75.36 per share to cover tax obligations from vested restricted stock units. After this tax-withholding disposition, she directly owned 28,052 Hologic shares.
Hologic Inc. director Amy McBride reported an acquisition of 3,190 shares of common stock in the form of restricted stock units. These units vest on the date of the 2027 Annual Meeting of Stockholders and will be settled one-for-one in common shares, bringing her direct holdings to 25,784 shares.
Hologic director Stacey D. Stewart reported an equity grant of 3,190 restricted stock units on February 26, 2026. The award has no cash exercise price and will vest on the date of the 2027 Annual Meeting of Stockholders, then be settled in shares of common stock.
After this grant, Stewart directly holds 8,358 shares and units in total, including 3,436 restricted stock units whose settlement has been deferred under Hologic’s Deferred Equity Plan.
Stamoulis Christiana reported acquisition or exercise transactions in this Form 4 filing.
Hologic Inc. director Christiana Stamoulis reported an equity award of 3,190 restricted stock units (RSUs) of common stock. The RSUs were granted at no cash purchase price and will vest on the date of Hologic’s 2027 Annual Meeting of Stockholders.
Each restricted stock unit will be settled in one share of Hologic common stock on a one-for-one basis. After this award, Stamoulis directly holds 50,526 shares of Hologic common stock, reflecting her updated ownership position as reported in the filing.
Hologic Inc. director Nanaz Mohtashami received an equity award in the form of restricted stock units. On the reported date, she acquired 3,190 RSUs at no cash cost, classified as a grant or award acquisition. Following this grant, she now holds 7,371 shares of common stock in direct ownership.
The footnotes explain that these RSUs will vest on the date of Hologic’s 2027 Annual Meeting of Stockholders and will be settled in shares of common stock on a one-for-one basis, linking director compensation directly to future stock performance.
McMillan Wayde D. reported acquisition or exercise transactions in this Form 4 filing.
Hologic, Inc. director Wayde D. McMillan reported receiving an equity award of 3,190 restricted stock units of common stock. The award was granted at no cash cost per share and will vest on the date of Hologic’s 2027 Annual Meeting of Stockholders.
Each restricted stock unit will be settled in one share of Hologic common stock upon vesting. Following this grant, McMillan’s directly held common stock position increased to 4,932 shares, reflecting his equity-based alignment with shareholders.
Madaus Martin D reported acquisition or exercise transactions in this Form 4 filing.
Hologic director Martin D. Madaus reported an equity award of 3,190 restricted stock units of common stock on February 26, 2026. These units vest on the date of the 2027 Annual Meeting of Stockholders and are settled one-for-one in Hologic common shares.
After this grant, Madaus directly holds 5,396 common shares. A separate line shows indirect ownership of 5,445 common shares through a revocable trust, reflecting his holdings in that entity.
Hologic director Ludwig Hantson received an equity award in the form of restricted stock units. On the reported date, he was granted 3,190 RSUs tied to Hologic common stock at no cash cost, classified as a grant or award acquisition. These RSUs are scheduled to vest on the date of the 2027 Annual Meeting of Stockholders and will be settled one-for-one in shares of common stock. After this award, Hantson’s directly held stake is 16,146 shares, which includes 3,695 RSUs whose settlement has been deferred under Hologic’s Deferred Equity Plan.
Hologic Inc. director Charles J. Dockendorff acquired 3,190 restricted stock units of common stock as a grant. The award was recorded at a price of $0.0000 per share, reflecting a stock-based compensation grant rather than a market purchase.
These restricted stock units vest on the date of Hologic’s 2027 Annual Meeting of Stockholders and are settled in shares of common stock on a one-for-one basis. After this grant, Dockendorff directly holds 6,626 shares of common stock, and indirectly holds 15,370 shares through a revocable trust.
Hologic executive Mark W. Horvath, President of Breast & Skeletal Health, reported a small administrative share disposition related to taxes. On February 10, 2026, 113 shares of common stock were withheld at $75.15 per share to cover tax obligations from settling restricted stock units.
After this tax-withholding transaction, Horvath directly beneficially owns 23,026 shares of Hologic common stock. This total includes 4,605 performance stock units/restricted stock units whose settlement has been deferred under Hologic’s Deferred Equity Plan.
Hologic, Inc. insider filing amendment: SVP of Human Resources Ms. De Walt reported that 4,416 shares of Hologic common stock were withheld on 01/30/2026 to satisfy tax obligations tied to vested restricted stock units at a price of $74.93 per share. After this tax withholding, she directly beneficially owned 7,603 Hologic shares.
This document is an amendment to a prior Form 4 and was filed solely to attach the correct Power of Attorney. The underlying transactions and share amounts remain unchanged from the original report.
Hologic, Inc. senior vice president Diana De Walt reported a routine tax‑withholding transaction in company stock. On January 30, 2026, 4,416 shares of Hologic common stock were withheld at $74.93 per share to cover tax obligations from vested restricted stock units.
After this Form 4 transaction, De Walt directly beneficially owned 7,603 shares of Hologic common stock. The filing describes no open‑market purchase or sale; the shares were retained by the company solely to satisfy tax withholding tied to equity compensation.
Hologic executive President, GYN Surgical reported a routine tax-related stock transaction. On December 12, 2025, 90 shares of Hologic common stock were disposed of at $75 per share as shares were withheld to satisfy tax obligations tied to vested restricted stock units. Following this withholding, the officer directly beneficially owns 17,512 Hologic shares.
Hologic, Inc. insider equity update: The Chairman, President and CEO, who is also a director of Hologic, Inc. (HOLX), reported a routine equity transaction dated 11/14/2025. A total of 6,874 shares of common stock were withheld at a price of $74.15 per share to cover tax obligations arising from the settlement of previously granted restricted stock units whose service-based vesting conditions had been met. After this tax withholding, the reporting person beneficially owns 1,423,837 shares of Hologic common stock directly and 1,146,829 shares indirectly through the MacMillan Family Trust. The indirect holdings include 1,079,673 restricted stock units/performance stock units for which settlement has been deferred under the company’s Deferred Equity Plan.
Hologic Inc. executive reports small tax-related share withholding
Hologic Inc. Group President, International reported a routine equity transaction involving the company’s common stock. On 11/14/2025, 196 shares of Hologic common stock were withheld at a price of $74.15 per share to cover tax obligations tied to the settlement of previously granted restricted stock units whose service-based vesting conditions had been met. Following this withholding transaction, the executive directly beneficially owns 134,039 shares of Hologic common stock.
Hologic, Inc. reported an insider equity transaction involving one of its officers. The President of GYN Surgical had 178 shares of Hologic common stock withheld on 11/14/2025 at a price of $74.15 per share, coded as an "F" transaction, which indicates shares were withheld to cover tax obligations related to previously granted restricted stock units whose service-based vesting conditions had been met. After this tax withholding, the officer directly beneficially owns 17,602 shares of Hologic common stock.
Hologic, Inc. insider reports tax-related share withholding
A Hologic executive, identified as President, Diagnostic Solutions, reported a routine equity transaction involving company common stock. On 11/14/2025, 561 shares of Hologic common stock were disposed of at $74.15 per share under transaction code “F,” which indicates shares were withheld to cover tax obligations upon settlement of previously granted restricted stock units whose service-based vesting conditions had been met. After this transaction, the executive beneficially owns 41,318 shares of Hologic common stock in direct ownership. No derivative securities transactions were reported in this filing.
Hologic Inc. Chief Financial Officer Form 4 filing details insider share activity. On 11/14/2025, the CFO reported the disposition of 1,333 shares of Hologic common stock at $74.15 per share, labeled as shares withheld to cover tax obligations related to the settlement of previously granted restricted stock units whose service-based vesting conditions were satisfied.
After this tax withholding transaction, the CFO beneficially owns 150,735 shares in total. This figure includes 41,121 restricted stock units and performance stock units whose settlement has been deferred under Hologic’s Deferred Equity Plan.
Hologic, Inc. (HOLX) reported an insider equity transaction by its Chief Operating Officer on a Form 4. On 11/14/2025, the COO had 1,342 shares of common stock withheld at a price of $74.15 per share.
According to the explanation, these shares were withheld to cover tax obligations arising from the settlement of restricted stock units whose service-based vesting conditions had been met. After this tax withholding transaction, the officer directly beneficially owned 77,610 shares of Hologic common stock.
Hologic Inc. (HOLX) disclosed an insider equity transaction by its General Counsel on a Form 4. On 11/14/2025, 337 shares of Hologic common stock were disposed of at $74.15 per share under transaction code "F", meaning the shares were withheld to cover tax obligations related to the settlement of previously granted restricted stock units whose service-based vesting conditions had been met. After this tax withholding, the officer directly beneficially owns 28,237 shares of Hologic common stock.
Hologic, Inc. (HOLX) reported an insider tax-withholding transaction by its Principal Accounting Officer. On 11/14/2025, the officer had 187 shares of common stock withheld, coded as an "F" transaction, at a price of $74.15 per share. This type of transaction reflects shares withheld to cover tax obligations tied to the settlement of previously granted restricted stock units whose service-based vesting conditions had been met. After this event, the officer beneficially owned 17,884 shares of Hologic common stock directly.